We Give Shareholders a Voice
Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Cascadian Therapeutics, Inc. (“Cascadian Therapeutics” or the “Company”) (NASDAQ: CASC) to Seattle Genetics, Inc. (NASDAQ: SGEN) for $10.00 per share.
The investigation concerns whether the Board of Cascadian Therapeutics breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Seattle Genetics, Inc. is underpaying for Cascadian Therapeutics shares, thus unlawfully harming Cascadian Therapeutics shareholders.
To receive more information, please fill out the form.